Heron Therapeutics - HRTX Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12-month price targets for Heron Therapeutics' shares. Their HRTX share price forecasts range from $5.50 to $12.00. On average, they anticipate the company's share price to reach $8.75 in the next twelve months. This suggests a possible upside of 92.7% from the stock's current price.
View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts.

Heron Therapeutics' stock was trading at $9.13 at the beginning of 2022. Since then, HRTX stock has decreased by 50.3% and is now trading at $4.54.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our HRTX earnings forecast.

Heron Therapeutics, Inc. (NASDAQ:HRTX) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.05. The biotechnology company had revenue of $27.63 million for the quarter, compared to analysts' expectations of $24.65 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 457.73% and a negative net margin of 239.34%. The firm's revenue was up 23.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.62) EPS.

Heron Therapeutics updated its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $93.00 million-$95.00 million, compared to the consensus revenue estimate of $106.69 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HRTX stock can currently be purchased for approximately $4.54.

Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $465.94 million and generates $86.35 million in revenue each year. The biotechnology company earns $-220,680,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

The company employs 302 workers across the globe.

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.herontx.com. The biotechnology company can be reached via phone at (858) 251-4400, via email at ir@herontx.com, or via fax at 650-365-6490.